Full-Time

Office Administrator

Posted on 10/7/2025

Deadline 10/20/25
Roche

Roche

1-10 employees

Global pharmaceuticals and diagnostics company

Compensation Overview

$67.8k - $125.8k/yr

+ Bonus

Washington, DC, USA

In Person

This position requires in-person attendance Monday through Friday during regular business hours. Relocation benefits are not available for this job posting.

US Top Secret Clearance Required

Category
Administrative & Executive Assistance (1)
Requirements
  • Ability to handle routine and impromptu assignments with minimal supervision
  • Ability to handle and exercise judgment and discretion concerning sensitive, confidential, and proprietary information
  • Demonstrates accuracy and attention to detail of own and others' work
  • Confident operating within a well-defined job scope and a shared decision-making process
  • In-depth knowledge of Microsoft Office (PowerPoint, Excel and Word), cSuite Tools Ad(including Gmail, gCal, gSheets, gSlides, Trello, Jamboard, gMeet, ZOOM)
  • Must demonstrate outstanding office management and administrative capabilities with a proven record of meeting defined objectives and goals.
  • Outstanding time management, organizational, and project management skills, as evidenced through past performance, track record and results.
  • Strong attention to detail in the creation/editing of department materials and specific proficiencies in the production of documents, presentations and spreadsheets.
  • Strong communication skills, both written and verbal. Communicates clearly, concisely, thoroughly and promptly with internal and external partners/stakeholders
  • Outstanding partnering skills. Works collaboratively, effectively, and efficiently with internal and external partners to meet the goals and objectives of the department.
  • The candidate must be a motivated individual who can demonstrate a proactive approach and an ability to streamline and reduce unnecessary administrative or operational burdens for the team.
  • Strong organizational and project coordination skills with a willingness to take initiative.
  • Display professionalism in all internal and external endeavors.
  • Note: Based on the external-facing nature of the position, this role is expected to be in-person Monday through Friday during regular business hours.
  • Core Competencies: Teamwork and Collaboration, Communication, Achieving Results
  • Must exhibit core values: Trust, Transparency, Collaboration, and Respect
Responsibilities
  • Manage office operations, including coordination with building management, security, and PA&A leadership
  • Handle all guest and employee interactions with the highest level of professionalism and customer service mindset to ensure we are always exceeding expectations.
  • Manage reception area operations, including managing the visitor’s log, greeting guests, collecting incoming mail, shipping outgoing mail, validating parking, receiving packages and shipments, and answering phones
  • Manage scheduling of conference rooms with both internal and external stakeholders (onsite, offsite, live or virtual)
  • Troubleshoot and manage IT, building, and Site Services requests
  • Order and maintain office supplies (e.g., copy room and kitchen resources)
  • Manage purchase orders, invoices, payment tracking, and vendor maintenance
  • Oversee new hire logistical onboarding (e.g., acquire security fobs and parking passes as needed)
  • Support the planning and execution of department or office staff meetings, meeting logistics including agenda creation/distribution, meeting materials, catering, room set-up, etc.
  • Manage communications for day-to-day office operations, including changes in policies, process, department reminder and team agreements
  • Plan and coordinate office events (employee engagement, community-driven, informal)
  • Serve as the internal and external face/liaison between the team and Genentech, acting appropriately and professionally
  • Possess a general knowledge of available Genentech IT systems such as cSuite, virtual conference tools, etc
  • Contribute to a team culture of innovation, enterprise-level thinking, collaboration, and impact
  • Provide administrative business support to PA&A teams and departments (based on business need), including but not limited to calendering, contracting, event support, and expense reporting.
Desired Qualifications
  • experience gained in the pharmaceutical/biotechnology industry is preferred
  • Familiarity with the Genentech organization preferred

Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.

Company Size

1-10

Company Stage

IPO

Headquarters

Basel, Switzerland

Founded

1896

Simplify Jobs

Simplify's Take

What believers are saying

  • PathAI acquisition for $750M in 2026 scales AI-driven digital pathology globally.
  • C4 Therapeutics DAC partnership yields up to $1B in next-gen cancer therapies.
  • CT-388 weight-loss drug targets double-digit share against Novo Nordisk, Eli Lilly.

What critics are saying

  • Swiss franc appreciation erodes 70% international revenue immediately.
  • Avastin, Herceptin patents expire 2028, Amgen biosimilars capture 50% share.
  • Tempus-Epic AI pathology platform steals 30% deals from PathAI by Q3 2026.

What makes Roche unique

  • Pioneered mass production of synthetic vitamin C in 1934 as Redoxon.
  • Acquired Genentech majority stake in 1990, entering biotechnology leadership.
  • Secured PCR technology rights from Cetus in 1991 for diagnostics dominance.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Company News

Dealroom.co
Apr 16th, 2026
SAGA company information, funding & investors

SAGA, providing cancer companion diagnostic testing of tissue and non-invasive monitoring of circulating tumor dna (ctdna). Here you'll find information about their funding, investors and team.

Yahoo Finance
Apr 13th, 2026
Roche receives CE mark for Elecsys NfL blood test to detect neuroinflammation in multiple sclerosis

Roche has received CE mark approval for its Elecsys Neurofilament Light Chain blood test to detect neuroinflammation in adults with relapsing remitting multiple sclerosis. The test measures NfL, a protein released during nerve cell injury, providing insight into neuroaxonal damage associated with the disease. Multiple sclerosis affects over 2.9 million people worldwide. Whilst early and regular monitoring is critical, patients often struggle to access routine MRI scans. The minimally invasive blood test offers a more accessible alternative, complementing clinical assessments and potentially enabling earlier intervention. The test runs on Roche's widely available cobas instruments, delivering standardised results and requiring only a simple blood sample. This reduces the need for patients to travel to specialist centres, making frequent monitoring more practical where traditional testing faces geographic, financial or logistical barriers.

Bizwatch
Apr 12th, 2026
Roche invests $20M in degrader-antibody conjugate platform via C4 Therapeutics deal worth up to $1B

Roche has partnered with C4 Therapeutics to develop degrader-antibody conjugates (DACs), marking a $20 million upfront payment with potential milestone payments exceeding $1 billion. The collaboration targets cancer therapeutics using C4's Torpedo platform. DACs represent a next-generation approach to antibody-drug conjugates (ADCs). Whilst ADCs attach cytotoxic drugs to antibodies, DACs use targeted protein degradation payloads to selectively eliminate specific proteins within cancer cells, potentially reducing toxicity and drug resistance whilst accessing previously difficult targets. Amongst Korean listed companies, Orum Therapeutics leads DAC development, having licensed ORM-6151 to Bristol Myers Squibb in 2023. Y-Biologics partnered with Ubix Therapeutics, whilst Oscotec is developing three DAC pipelines through subsidiary Genosco, targeting technology transfers after 2028.

Yahoo Finance
Mar 30th, 2026
Roche gets FDA clearance for cobas c703 and ISE neo lab testing units with 2,000 tests per hour

Roche has received FDA 510(k) clearance for its cobas c703 and cobas ISE neo analytical units, designed to enhance laboratory efficiency through increased automation and testing capacity. The units are part of Roche's cobas pro integrated solutions platform. The cobas c703 delivers up to 2,000 tests per hour with 70 reagent positions, doubling clinical chemistry throughput whilst reducing reagent reloads. The cobas ISE neo provides up to 1,800 tests per hour with automated maintenance, reducing hands-on time and plastic waste compared to previous systems. Both units feature monthly operator maintenance to improve uptime and help laboratories address staffing shortages and growing test volumes. Roche has over 4,000 cobas analysers installed across the United States.

Yahoo Finance
Mar 30th, 2026
Roche launches cobas MPX-E assay, 4-in-1 donor screening test for HIV, HCV, HBV and HEV

Roche has launched the cobas MPX-E assay, a four-in-one donor screening test that simultaneously detects HIV, Hepatitis C, B and E viruses. The test is now available in countries accepting the CE mark. The assay consolidates detection of four major viral targets into a single workflow, improving laboratory efficiency and reducing costs. It features dual-target detection for HIV-1 and enhanced sensitivity for Hepatitis E, which causes an estimated 20 million infections and 70,000 deaths annually worldwide. The test runs on Roche's fully automated cobas x800 systems, which process over 10 million tests monthly across laboratories globally. The ready-to-load reagents enable up to eight hours of walk-away time. The nucleic acid testing blood screening market is valued at approximately 800 million Swiss francs globally, with an expected annual growth rate of 2% through 2029.

INACTIVE